Compare Stocks → This could mean the end of the U.S dollar… (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:COGTNASDAQ:DNTHNASDAQ:PHARNASDAQ:SIGA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$8.22+9.7%$6.94$3.67▼$13.50$785.91M1.571.84 million shs1.00 million shsDNTHDianthus Therapeutics$22.55+3.6%$25.29$6.58▼$33.77$661.82M1.77139,492 shs122,810 shsPHARPharming Group$9.31+2.9%$10.19$8.71▼$16.71$626.94M0.22,692 shs5,404 shsSIGASIGA Technologies$7.46+0.1%$8.58$4.22▼$10.83$530.56M0.95765,889 shs436,060 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-6.72%+0.27%+7.61%+0.67%-35.43%DNTHDianthus Therapeutics-5.55%-17.07%-7.05%-10.92%+2,176,999,900.00%PHARPharming Group-2.70%-5.55%-6.77%-20.81%-27.84%SIGASIGA Technologies-0.40%-5.70%-14.95%+40.04%+31.16%Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences2.1821 of 5 stars4.42.00.00.02.10.00.6DNTHDianthus Therapeutics1.026 of 5 stars3.50.00.00.02.71.70.0PHARPharming Group1.8685 of 5 stars3.53.00.00.02.70.00.6SIGASIGA Technologies0.126 of 5 stars0.01.00.00.01.70.81.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences2.71Moderate Buy$14.6778.43% UpsideDNTHDianthus Therapeutics3.00Buy$42.8389.95% UpsidePHARPharming Group3.00Buy$37.00297.42% UpsideSIGASIGA TechnologiesN/AN/AN/AN/ACurrent Analyst RatingsLatest SIGA, DNTH, COGT, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/24/2024COGTCogent BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.005/16/2024DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/13/2024COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.005/10/2024DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $38.005/8/2024COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.004/18/2024DNTHDianthus TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $51.003/22/2024DNTHDianthus TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $39.003/22/2024DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $33.003/14/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.002/27/2024COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $20.002/26/2024COGTCogent BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.00(Data available from 5/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$2.09 per shareN/ADNTHDianthus Therapeutics$3.22M205.28N/AN/A$12.70 per share1.78PHARPharming Group$245.32M2.56$0.10 per share95.11$3.06 per share3.04SIGASIGA Technologies$139.92M3.79$0.96 per share7.75$2.32 per share3.22Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$192.41M-$2.48N/AN/AN/AN/A-91.56%-55.20%8/13/2024 (Estimated)DNTHDianthus Therapeutics-$43.56M-$5.83N/AN/AN/AN/A-20.82%-19.86%8/1/2024 (Estimated)PHARPharming Group-$10.55M-$0.16N/A46.55N/A-4.01%-4.61%-2.18%8/1/2024 (Estimated)SIGASIGA Technologies$68.07M$1.106.786.97N/A50.48%51.97%39.51%8/13/2024 (Estimated)Latest SIGA, DNTH, COGT, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024Q1 2024COGTCogent Biosciences-$0.51-$0.62-$0.11-$0.62N/AN/A3/21/2024Q4 2023DNTHDianthus Therapeutics-$1.11-$0.71+$0.40-$0.71$0.73 million$0.46 million3/14/2024Q4 2023PHARPharming Group$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 million3/12/2024Q4 2023SIGASIGA TechnologiesN/A$1.01+$1.01$1.01N/A$116.48 million2/26/202412/31/2023COGTCogent Biosciences-$0.55-$0.63-$0.08-$0.63N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ALatest SIGA, DNTH, COGT, and PHAR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/12/2024SIGASIGA Technologies$0.603/25/20243/26/20244/11/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A12.0512.05DNTHDianthus TherapeuticsN/A42.5242.52PHARPharming GroupN/A1.431.16SIGASIGA TechnologiesN/A3.052.19OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ADNTHDianthus Therapeutics47.53%PHARPharming Group0.03%SIGASIGA Technologies55.40%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences5.92%DNTHDianthus Therapeutics16.56%PHARPharming Group2.07%SIGASIGA Technologies1.54%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences16495.61 million89.95 millionOptionableDNTHDianthus Therapeutics5329.35 million24.49 millionNo DataPHARPharming Group38267.34 million65.95 millionNot OptionableSIGASIGA Technologies4571.12 million70.03 millionOptionableSIGA, DNTH, COGT, and PHAR HeadlinesRecent News About These CompaniesMay 20, 2024 | marketbeat.comSIGA Technologies (NASDAQ:SIGA) Shares Gap Down to $7.61May 17, 2024 | zacks.comNew Strong Buy Stocks for May 17thMay 16, 2024 | americanbankingnews.comTraders Purchase High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)May 16, 2024 | americanbankingnews.comFY2024 EPS Estimates for SIGA Technologies, Inc. (NASDAQ:SIGA) Cut by Edison Inv. ResMay 15, 2024 | marketbeat.comResearch Analysts Issue Forecasts for SIGA Technologies, Inc.'s FY2024 Earnings (NASDAQ:SIGA)May 15, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for SIGA Technologies, Inc.'s FY2025 Earnings (NASDAQ:SIGA)May 14, 2024 | marketbeat.comEdison Inv. Res Equities Analysts Decrease Earnings Estimates for SIGA Technologies, Inc. (NASDAQ:SIGA)May 11, 2024 | bovnews.comThe market value of SIGA Technologies Inc (SIGA) Stock is expected to soar in the coming monthsMay 11, 2024 | marketbeat.comLos Angeles Capital Management LLC Sells 192,930 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)May 10, 2024 | zacks.comIs Siga Technologies (SIGA) Stock Undervalued Right Now?May 10, 2024 | finance.yahoo.comSIGA Technologies First Quarter 2024 Earnings: EPS: US$0.14 (vs US$0.013 loss in 1Q 2023)May 8, 2024 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comSIGA Technologies (NASDAQ:SIGA) Sees Unusually-High Trading VolumeMay 7, 2024 | msn.comSIGA Stock Earnings: SIGA Technologies Reported Results for Q1 2024May 7, 2024 | globenewswire.comSIGA Reports Financial Results for Three Months Ended March 31, 2024May 6, 2024 | marketbeat.comSIGA Technologies (NASDAQ:SIGA) Stock Price Up 5.3%May 3, 2024 | marketbeat.comSIGA Technologies (NASDAQ:SIGA) Reaches New 1-Year High at $10.17May 3, 2024 | zacks.comSiga Technologies (SIGA) Upgraded to Strong Buy: Here's What You Should KnowMay 3, 2024 | zacks.comNew Strong Buy Stocks for May 3rdMay 3, 2024 | zacks.comBest Value Stocks to Buy for May 3rdMay 2, 2024 | msn.comFuertes lluvias causan inundaciones en área metropolitana de Houston; ordenan a residentes evacuarNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCogent BiosciencesNASDAQ:COGTCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Dianthus TherapeuticsNASDAQ:DNTHDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.SIGA TechnologiesNASDAQ:SIGASIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.